Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of December 2024, specifically dated December 19, 2024. The report serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory disclosure of a specific executive transaction rather than a financial performance report.
Material Changes
The material change disclosed is the grant of a share option to a senior executive. There are no reported changes to the company's financial position or operational status in this filing.
Management Commentary and Unusual Items
The filing details an initial notification of a transaction involving Adrian Morris, the General Counsel and a PDMR. On December 19, 2024, Mr. Morris was granted a 3-year option over 6,150 Ordinary Shares under the 2024 Haleon Share Save Plan. The transaction occurred outside a trading venue with an exercise price of £3.00 per share. These options will first become exercisable on February 1, 2028.
Investor Verification Checklist
- Verify the terms of the 2024 Haleon Share Save Plan to understand vesting conditions and dilution impact.
- Confirm the current market price of Haleon Ordinary Shares relative to the £3.00 exercise price.
- Review the total number of options granted to PDMRs in the current fiscal year to assess aggregate compensation trends.
- Check subsequent filings for the actual exercise or expiration of these options in 2028.